Bookmark

Add to MyYahoo RSS

Bloomsbury Publishing News

News on Bloomsbury Publishing (Ticker: BMY) continually updated from thousands of sources around the net.

11 hrs ago | Pharmaceutical Technology

Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies

Bristol-Myers Squibb and Ono Pharmaceutical signed a collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea, and Taiwan.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry, Health, Lung Cancer

Sat Jul 26, 2014

AmericanBankingNews.com

Bristol-Myers Squibb Given "Neutral" Rating at Zacks

's stock had its "neutral" rating reiterated by Zacks in a report issued on Friday.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex

Fri Jul 25, 2014

Seeking Alpha

Why Bristol-Myers Squibb Loses Out Against This Rival

We pitch two companies from the GICS sector 'health care distributors and services', Bristol-Myers Squibb and Express Scripts, against one another in the latest instalment of our Head-To-Head series.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Social Solutions, Express Scripts, Publishing, Media, Medarex, Pharmaceuticals

BioSpace

BioMed Realty And Bristol-Myers Squibb Company Sign Lease To Expand ...

BioMed Realty And Bristol-Myers Squibb Company Sign Lease To Expand Relationship To 194,100 Square Feet At Woodside Technology Park In Redwood City, California /PRNewswire/ -- BioMed Realty Trust, Inc. today announced that Bristol-Myers Squibb has signed a ten-year lease for approximately 61,000 square feet of additional laboratory and office space ... (more)

Comment?

Related Topix: Bristol Myers Squibb, Biotech, Medicine, Healthcare Industry, BioMed Realty Trust, Publishing, Media, Medarex, San Mateo County, CA, Redwood City, CA

Thu Jul 24, 2014

Benzinga

Thursday Morning Earnings Reports

American Airlines Group reported its Q2 earnings with EPS of $1.98 compared to analyst estimates of $1.95 and revenue of $11.36 billion compared to estimates of $11.33 billion.

Comment?

Related Topix: Alaska Air Group, Airlines, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Healthcare Industry, Camping World, Retail, Cabela's, Mobile Homes, Sporting Goods

BioSpace

Bristol-Myers Squibb Company Appoints As India Country Head

Bristol-Myers Squibb India appointed Jitendra Tyagi as the BMS India country head.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals

Wed Jul 23, 2014

GlobeNewswire

Innate Pharma : Completion of target enrollment in the phase II EffiKIR trial

Innate Pharma SA , the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announced completion of target enrollment in the EffiKIR trial with 150 patients randomized.

Comment?

Related Topix: Health, Leukemia, Bristol Myers Squibb, Biotech, Healthcare Industry, Media, Publishing, Medarex

Customer Interaction Solutions

Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce...

Ono Pharmaceutical Co., Ltd. have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry, Health, Lung Cancer

The Motley Fool

Earnings Preview: Bristol-Myers Squibb and Celgene Corporation

Most health care stocks have been experiencing a roller coaster ride so far this year.

Comment?

Related Topix: Bristol Myers Squibb, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Biotech, Celgene, Medicine, Healthcare Industry

Forbes.com

Forbes Earnings Preview: Bristol Myers Squibb

Bristol Myers Squibb reports its second-quarter earnings on Thursday, July 24, 2014, and the consensus earnings per share estimate is 45 cents per share.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry, Financial Markets

Tue Jul 22, 2014

AmericanBankingNews.com

Bristol-Myers Squibb Given Average Rating of "Buy" by Analysts

Bristol-Myers Squibb has been given a consensus rating of "Buy" by the seventeen analysts that are presently covering the stock, Analyst Ratings News reports .

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex

Thu Jul 17, 2014

Value Line

Drug Roundup - July 17, 2014

There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve.

Comment?

Related Topix: Pfizer, Biotech, Medicine, Healthcare Industry, Merck , Eli Lilly, Bristol Myers Squibb, Publishing, Media, Pharmaceuticals

BioSpace

Bristol-Myers Squibb Company And Pfizer Inc. Announce Enrollment Of...

Bristol-Myers Squibb Company And Pfizer Inc. Announce Enrollment Of First Patient In Phase IV EMANATE Trial To Assess Effectiveness And Safety Of Eliquis In Patients With NVAF Undergoing Cardioversion PRINCETON, N.J. & NEW YORK-- --Bristol-Myers Squibb Company and Pfizer Inc. today announced that the first patient has been enrolled into a Phase IV ... (more)

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Pfizer, Princeton, NJ, Publishing, Media, Medarex, Excaliard Pharmaceuticals

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Net income for the quarter ended June 30, 2014 was $3,873,000 or $1.82 ... )--ISIN XS0179021133 Issuer Name GREENLAND CDO LTD Paying Agent HSBC BANK PLC Redemption Type REPURCHASE Currency EUR O/S Balance 244,020,000.00 New Balance 0 .0... )--FUND A db x-trackers MSCI JAPAN TRN INDEX UCITS ETF DEALING DATE A 15-Jul-14 NAV PER SHARE A USD47.7014 ... (more)

Comment?

Related Topix: RiskMetrics, MSCI, Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex, Pfizer

Mon Jul 14, 2014

Seeking Alpha

Is Bristol-Myers Squibb Overvalued?

Bristol-Myers's stock price has been lowered by analysts but they still expect the future price to be above the current price of the stock.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex, Gilead Sciences, Oncology

Thu Jul 10, 2014

The Motley Fool

Top Biotech Stocks to Watch Today: Allergan, Arena Pharmaceuticals and Bristol-Myers Squibb

Let's take a look at today's top stories in biotech and health care. Keep an eye out for Allergan .

Comment?

Related Topix: Bristol Myers Squibb, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Allergan, Biotech

Pharmaceutical Processing

Bristol-Myers Squibb Makes Plans to Submit Biologics License Application for OpdivoA

Bristol-Myers Squibb Company today announced that, following discussions with the U.S. Food and Drug Administration , the company is planning a third quarter submission of a Biologics Licensing Application for OpdivoA for previously treated advanced melanoma.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Law, Law

Book trade news from Book2book

Bloomsbury Publishing 3-month Revenues Down 9%

Bloomsbury Publishing Plc reported that in the three months ended 31 May 2014, total revenues were down by 9% on last year , but are up by 7% when compared to the three months ended 31 May 2012.

Comment?

Related Topix: Publishing, Media

HIV and Hepatitis

Interferon-free Daclatasvir + Asunaprevir Approved in Japan for Hepatitis C

Bristol-Myers Squibb's all-oral dual regimen of daclatasvir plus asunaprevir has been approved for the treatment of chronic hepatitis C in Japan, where most people are infected with HCV genotype 1b, the company announced this week.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Bristol Myers Squibb, Healthcare Industry, Publishing, Media, Medarex, Food and Drug Administration

Tue Jul 08, 2014

AmericanBankingNews.com

Bristol-Myers Squibb Given New $55.00 Price Target at Leerink Swann

Leerink Swann's price objective would suggest a potential upside of 14.92% from the stock's previous close.

Comment?

Related Topix: Bristol Myers Squibb, Biotech, Medicine, Healthcare Industry, Bristol-Myers Squibb, Media, Publishing, Medarex, Pharmaceuticals

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••